---
title: "Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap"
description: How population PK, allometric scaling, and exposure-response simulation can support pediatric dose selection when pediatric data are scarce, with the cabozantinib example.
image: https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

Nov 22, 2026

# Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap

How population PK, allometric scaling, and exposure-response simulation can support pediatric dose selection when pediatric data are scarce, with the cabozantinib example.

![Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap](https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png)\\

Pediatric indications are still approved well after adult ones. The reasons are complex, but one recurring hurdle is translating an adult dosing regimen into one that is safe and effective for children and adolescents, often with very few pediatric patients available to study.

Model-informed drug development (MIDD) offers a practical way through. By building on the adult data a program already has, sponsors can simulate exposure in pediatric patients, identify where adult doses would over- or under-expose them, and propose an adjusted regimen before, or instead of, a large dedicated pediatric trial.

## The building blocks

- **Population pharmacokinetics (popPK).** A popPK model describes typical drug exposure and how covariates such as body weight, age, organ function, and concomitant medications shift it. It is the core tool for predicting exposure in a population that has not been dosed.
- **Allometric scaling.** Clearance and volume do not scale linearly with body weight. Allometric exponents capture this, so a model built in adults can be extrapolated to smaller patients in a physiologically sensible way.
- **Exposure-response (ER) models.** Once exposure is predicted, ER relationships for efficacy and safety show whether a candidate regimen is expected to keep benefit while holding adverse events to a tolerable level.
- **Physiologically based PK (PBPK), when needed.** For very young children, where maturation of metabolic enzymes and transporters matters, PBPK models can complement popPK.

## A worked example: cabozantinib in adolescents

A published analysis of the Phase 3 COSMIC-311 program shows how this works in practice \[2\]. The authors developed a popPK model from 4,746 quantifiable cabozantinib PK samples from 1,745 individuals across seven studies. They then applied it to a simulated adolescent population whose body weights were sampled by age and sex from CDC weight-for-age data.

Using allometric scaling, they simulated the adult regimen of 60 mg daily in this virtual cohort. Adolescents weighing under 40 kg had elevated AUC, Cmin, and Cmax. Lowering the dose to 40 mg in that group brought exposure back within the 90% prediction interval of adult concentrations, and ER modeling predicted that efficacy would be maintained with tolerable adverse events. These simulations supported the cabozantinib labeling for adolescent patients with radioiodine-refractory differentiated thyroid cancer.

## From one-size-fits-all to precision dosing

The same toolkit underpins precision dosing more broadly. Once a model links patient characteristics to exposure and exposure to response, sponsors can:

- Identify subgroups, such as low body weight or impaired organ function, that need a different dose.
- Use interim PK and response data in adaptive designs to refine dosing during a trial rather than after it.
- Support labeling decisions with simulations instead of separate studies in every subgroup.
- Bring a quantitative rationale to early regulatory discussions. FDA, EMA, and other agencies increasingly expect MIDD evidence in pediatric and dose-selection packages.

## Why sample quality decides model quality

Every simulation in this workflow rests on measured concentrations. With sparse pediatric sampling, each data point carries more weight, so assay sensitivity, small sample volumes, stability, and consistent methods across studies and sites matter as much as the modeling. A popPK model built on noisy or inconsistent bioanalytical data will propagate that noise into the dose recommendation.

Crystal Bio Solutions supports these programs end to end, from validated PK and biomarker assays suited to low-volume pediatric samples through popPK, exposure-response, and dose-selection analyses. Learn more about our [clinical pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology) services, or [contact us](https://www.crystalbiosolutions.com/contact-us) to discuss your pediatric or dose-optimization strategy.

### References

1. Speer EM, Lee LK, Bourgeois FT, et al. The state and future of pediatric research: an introductory overview. *Pediatr Res*. 2023.
2. Ly NS, Li J, Faggioni R, Roskos LK, Brose MS. Population pharmacokinetics and exposure-response analysis for the Phase 3 COSMIC-311 trial of cabozantinib for radioiodine-refractory differentiated thyroid cancer. *Clin Pharmacokinet*. 2023;62(4):587-598.

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "CBS Marketing Team",
    "url" : "https://www.crystalbiosolutions.com/news-and-events/author/cbs-marketing-team"
  },
  "dateModified" : "2026-11-22T17:58:52.897Z",
  "datePublished" : "2026-11-22T17:58:52.000Z",
  "headline" : "Pediatric Dosing With Little Pediatric Data: How Population PK and Exposure-Response Simulation Fill the Gap",
  "image" : [ "https://www.crystalbiosolutions.com/hubfs/AI-Generated%20Media/Images/Researcher%20Analyzing%20Colorful%20Drug%20Vials%20In%20Sophisticated%20Lab.png" ],
  "mainEntityOfPage" : {
    "@id" : "https://www.crystalbiosolutions.com/news-and-events/pediatric-dosing-with-little-pediatric-data-how-population-pk-and-exposure-response-simulation-fill-the-gap",
    "@type" : "WebPage"
  },
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "url" : "https://www.crystalbiosolutions.com/hubfs/Crystal%20Bio%20Solutions%20logo.webp"
    },
    "name" : "Crystal Bio Solutions"
  }
}
```